Previous close | 1.6000 |
Open | 1.5800 |
Bid | 1.5100 x 1200 |
Ask | 1.5200 x 1000 |
Day's range | 1.5000 - 1.6089 |
52-week range | 1.1100 - 14.3800 |
Volume | |
Avg. volume | 2,469,677 |
Market cap | 96.995M |
Beta (5Y monthly) | 1.81 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.6700 |
Earnings date | 10 Aug 2022 - 15 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 9.33 |
Seagen (SGEN) is riding on the strong uptake of its marketed drugs that are approved for different cancer indications. Further label expansion of these drugs should boost the top line.
Graybug's (GRAY) board of directors is set to review strategic options focused on maximizing shareholder value, including a potential sale of the company. Shares rise.
Cybin (CYBN) receives a "may proceed letter" and IND application clearance from the FDA for a phase I/IIa study evaluating CYB003 for potential treatment of major depressive disorder. Shares up.